GLP-1 momentum drives 79% pharma M&A surge
GLP-1 therapies helped drive a 79% year-over-year increase in strategic pharmaceutical M&A deal value through mid-November 2025, as drugmakers ramped up efforts to meet surging demand and expand their metabolic portfolios. According to Bain & Co.’s Global M&A Report 2026, the spike in activity reflects a shift in strategy: Acquirers are no longer focused solely […]
Continue Reading